The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs
Abstract
Interactions between antiepileptic drugs, or between antiepileptic drugs and other drugs, can be pharmacokinetic or pharmacodynamic in nature. Pharmacokinetic interactions involve changes in absorption, distribution or elimination, whereas pharmacodynamic interactions involve synergism and antagonism at the site of action. Most clinically important interactions of antiepileptic drugs result from induction or inhibition of drug metabolism. Carbamazepine, phenytoin, phenobarbital and primidone are strong inducers of cytochrome P450 and glucuronizing enzymes (as well as P‐glycoprotein) and can reduce the efficacy of co‐administered medications such as oral anticoagulants, calcium antagonists, steroids, antimicrobial and antineoplastic drugs through this mechanism. Oxcarbazepine, eslicarbazepine acetate, felbamate, rufinamide, topiramate (at doses ≥200 mg/day) and perampanel (at doses ≥8 mg/day) have weaker inducing properties, and a lower propensity to cause interactions mediated by enzyme induction. Unlike enzyme induction, enzyme inhibition results in decreased metabolic clearance of the affected drug, the serum concentration of which may increase leading to toxic effects. Examples of important interactions mediated by enzyme inhibition include the increase in the serum concentration of phenobarbital and lamotrigine caused by valproic acid. There are also interactions whereby other drugs induce or inhibit the metabolism of antiepileptic drugs, examples being the increase in serum carbamazepine concentration by erythromycin, and the decrease in serum lamotrigine concentration by oestrogen‐containing contraceptives. Pharmacodynamic interactions between antiepileptic drugs may also be clinically important. These interactions can have potentially beneficial effects, such as the therapeutic synergism of valproic acid combined with lamotrigine, or adverse effects, such as the reciprocal potentiation of neurotoxicity observed in patients treated with a combination of sodium channel blocking antiepileptic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Summary of product characteristics
(2013) · Pharmaceutical Medicine · doi:10.1093/med/9780199609147.003.0027 · Cited by 1,905
Clinically relevant drug interactions with antiepileptic drugs
Perucca, E. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02529.x · Cited by 602
Self-citation(2004) · Wiley eBooks · doi:10.1002/9780470752463 · Cited by 508
The importance of drug interactions in epilepsy therapy
Patsalos, P. N., Fröscher, W., Pisani, F., & Van Rijn, C. M. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.13001.x · Cited by 455
Patsalos, P. N., & Perucca, E. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00409-5 · Cited by 423
Self-citationPatsalos, P. N., & Perucca, E. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00483-6 · Cited by 391
Self-citationEnzyme induction with antiepileptic drugs: Cause for concern?
Brodie, M. J., Mintzer, S., Pack, A. M., Gidal, B. E., Vecht, C. J., & Schmidt, D. (2013) · Epilepsia · doi:10.1111/j.1528-1167.2012.03671.x · Cited by 383
Drugs as P-glycoprotein substrates, inhibitors, and inducers
Kim, R. B. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001389 · Cited by 382
Zhou, S.-F., Xue, C. C., Yu, X.-Q., Li, C., & Wang, G. (2007) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31815c16f5 · Cited by 375
Antiepileptic drug interactions—Principles and clinical implications
I. Johannessen, S., & Johannessen Landmark, C. (2010) · Current Neuropharmacology · doi:10.2174/157015910792246254 · Cited by 343
Drug interactions involving the new second- and third-generation antiepileptic drugs
Johannessen Landmark, C., & Patsalos, P. N. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.136 · Cited by 321
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma
Weller, M., Gorlia, T., Cairncross, J. G., van den Bent, M. J., Mason, W., Belanger, K., Brandes, A. A., Bogdahn, U., Macdonald, D. R., Forsyth, P., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31822f02e1 · Cited by 290
Jerling, M., Lindström, L., Bondesson, U., & Bertilsson, L. (1994) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199408000-00006 · Cited by 281
Perucca, E., Cloyd, J. C., Critchley, D. J. P., & Fuseau, E. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01665.x · Cited by 260
Self-citationInteractions between antiepileptic and chemotherapeutic drugs
Vecht, C. J., Wagner, G. L., & Wilms, E. B. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00435-6 · Cited by 256
Sodium valproate acutely inhibits lamotrigine metabolism.
Yuen, A., Land, G., Weatherley, B., & Peck, A. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb04079.x · Cited by 252
Oral contraceptives reduce lamotrigine plasma levels
Sabers, A., Öhman, I., Christensen, J., & Tomson, T. (2003) · Neurology · doi:10.1212/01.wnl.0000076485.09353.7a · Cited by 250
Lamotrigine Clinical Pharmacokinetics
Rambeck, B., & Wolf, P. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199325060-00003 · Cited by 244
Drug and dietary interactions of warfarin and novel oral anticoagulants: an update
Nutescu, E., Chuatrisorn, I., & Hellenbart, E. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0561-1 · Cited by 243
Löscher, W., & Schmidt, D. (2006) · Epilepsia · doi:10.1111/j.1528-1167.2006.00607.x · Cited by 239
Lazarowski, A., Czornyj, L., Lubienieki, F., Girardi, E., Vazquez, S., & D'Giano, C. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01302.x · Cited by 239
Clinically Important Drug Interactions with Anticoagulants: An Update
Harder, S., & Thürmann, P. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199630060-00002 · Cited by 227
Oxcarbazepine Placebo‐Controlled, Dose‐Ranging Trial in Refractory Partial Epilepsy
(2000) · Epilepsia · doi:10.1111/j.1499-1654.2000.001597.x · Cited by 225
Depression and epilepsy: A bidirectional relation?
Kanner, A. M. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2010.02907.x · Cited by 225
Lamotrigine plasma levels reduced by oral contraceptives
Sabers, A., Buchholt, J. M., Uldall, P., & Hansen, E. L. (2001) · Epilepsy Research · doi:10.1016/s0920-1211(01)00305-9 · Cited by 219
Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions
Łuszczki, J. J. (2009) · Pharmacological Reports · doi:10.1016/s1734-1140(09)70024-6 · Cited by 208
Effect of phenytoin on plasma clozapine concentrations in two patients.
Preskorn, S. H., & Fast, G. A. (1991) · PubMed · Cited by 201
Sake, J.-K., Hebert, D., Isojärvi, J., Doty, P., De Backer, M., Davies, K., Eggert-Formella, A., & Zackheim, J. (2010) · CNS Drugs · doi:10.2165/11587550-000000000-00000 · Cited by 197
Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial
Tiihonen, J., Hallikainen, T., Ryynänen, O.-P., Repo-Tiihonen, E., Kotilainen, I., Eronen, M., Toivonen, P., Wahlbeck, K., & Putkonen, A. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00524-9 · Cited by 191
Sidhu, J., Job, S., Singh, S., & Philipson, R. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02539.x · Cited by 185
Patsalos, P. N. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0087-0 · Cited by 184
Oberndorfer, S., Piribauer, M., Marosi, C., Lahrmann, H., Hitzenberger, P., & Grisold, W. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-2338-2 · Cited by 183
Tucker, R. M., Denning, D. W., Hanson, L. H., Rinaldi, M. G., Graybill, J. R., Sharkey, P. K., Pappagianis, D., & Stevens, D. A. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/14.1.165 · Cited by 183
Pharmacokinetic Interactions of Topiramate
Bialer, M., Doose, D. R., Murthy, B., Curtin, C., Wang, S.-S., Twyman, R. E., & Schwabe, S. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443120-00001 · Cited by 182
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.1.123 · Cited by 170
Grimm, S. W., Richtand, N. M., Winter, H. R., Stams, K. R., & Reele, S. B. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02507.x · Cited by 169
GIESSMANN, T., MAY, K., MODESS, C., WEGNER, D., HECKER, U., ZSCHIESCHE, M., DAZERT, P., GRUBE, M., SCHROEDER, E., & WARZOK, R. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.04.011 · Cited by 167
Gex-Fabry, M., Balant-Gorgia, A. E., & Balant, L. P. (2003) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200302000-00007 · Cited by 167
Ethinyl Estradiol, Not Progestogens, Reduces Lamotrigine Serum Concentrations
Reimers, A., Helde, G., & Brodtkorb, E. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.10105.x · Cited by 165
Carbamazepine Toxicity with Lamotrigine: Pharmacokinetic or Pharmacodynamic Interaction?
Besag, F. M. C., Berry, D. J., Pool, F., Newbery, J. E., & Subel, B. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01356.x · Cited by 161
Increased carbamazepine plasma concentrations after fluoxetine coadministration
Grimsley, S. R., Jann, M. W., Carter, J. G., D’mello, A. P., & D’Souza, M. J. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.98 · Cited by 151
Löscher, W., Luna‐Tortós, C., Römermann, K., & Fedrowitz, M. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211797440212 · Cited by 149
Implications of Cytochrome P450 Interactions When Prescribing Medication for Hypertension
Flockhart, D. A., & Tanus-Santos, J. E. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.4.405 · Cited by 145
Brodie, M. J., Rosenfeld, W. E., Vázquez, B., Sachdeo, R., Perdomo, C. A., Mann, A., & Arroyo, S. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2009.02160.x · Cited by 144
Clinical Significance of Pharmacokinetic Interactions Between Antiepileptic and Psychotropic Drugs
Spina, E., & Perucca, E. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.043s2037.x · Cited by 143
Self-citationSpina, E., Avenoso, A., Facciolà, G., Salemi, M., Scordo, M. G., Giacobello, T., Madia, A. G., & Perucca, E. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200008000-00019 · Cited by 132
Self-citationClinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives
Reddy, D. S. (2010) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.10.3 · Cited by 124
Bidirectional interaction of valproate and lamotrigine in healthy subjects*
Anderson, G. D., Yau, M. K. T., Gidal, B. E., Harris, S. J., Levy, R. H., Lai, A. A., Wolf, K. B., Wargin, W. A., & Dren, A. T. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90130-7 · Cited by 123
Clinical Pharmacokinetics of Antiepileptic Drugs in Paediatric Patients
Battino, D., Estienne, M., & AVANZINI, G. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199529040-00005 · Cited by 121
Henriksen, O., & Johannessen, S. I. (1982) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1982.tb03106.x · Cited by 116
Olesen, O. V., & Línnet, K. (1999) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199902000-00013 · Cited by 109
A Review of Enzyme Induction of Warfarin Metabolism with Recommendations for Patient Management
Cropp, J. S., & Bussey, H. I. (1997) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1997.tb03782.x · Cited by 108
Time‐course of interaction between carbamazepine and clonazepam in normal man
Lai, A. A., Levy, R. H., & Cutler, R. E. (1978) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1978243316 · Cited by 107
New treatment guidelines for acute bipolar mania: A critical review
Nivoli, A., Murru, A., Goikolea, J. M., Crespo, J. M., Montes, J. M. G., González-Pinto, A. M., García‐Portilla, M. P., Bobes, J., Sáiz-Ruiz, J., & Vieta, E. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.10.015 · Cited by 103
Patsalos, P. N. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0088-z · Cited by 103
Quetiapine and Drug Interactions
Castberg, I., & Skogvoll, E. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1011 · Cited by 102
Trends in utilization of antiepileptic drugs in Denmark
Tsiropoulos, I., Gichangi, A., Andersen, M. T., Bjerrum, L., Gaist, D., & Hallas, J. (2006) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2006.00639.x · Cited by 101
Interaction Between Valproic Acid and Carbapenem Antibiotics
Mori, H., Takahashi, K., & Mizutani, T. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530701690341 · Cited by 100
Chiron, C. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2006.10.001 · Cited by 100
Walzer, M., Bekersky, I., Blum, R. A., & Tolbert, D. S. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2012.01028.x · Cited by 98
Lamotrigine toxicity secondary to sertraline
Kaufman, K. R., & Gerner, R. H. (1998) · Seizure · doi:10.1016/s1059-1311(98)80074-5 · Cited by 97
Clinically Significant Drug Interactions with Atypical Antipsychotics
Kennedy, W. K., Jann, M. W., & Kutscher, E. C. (2013) · CNS Drugs · doi:10.1007/s40263-013-0114-6 · Cited by 95
Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects
VANDERLEE, M., Dawood, L. H., TERHOFSTEDE, H., et al. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.04.014 · Cited by 94
Rash in Adult and Pediatric Patients Treated with Lamotrigine
Messenheimer, J. A. (1998) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100034910 · Cited by 92
Miceli, J. J., Anziano, R., Robarge, L., Hansen, R., & Laurent, A. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00157.x · Cited by 92
Pharmacokinetic Interactions with Antiepileptic Drugs
Perucca, E. (1982) · Clinical Pharmacokinetics · doi:10.2165/00003088-198207010-00004 · Cited by 91
Self-citationNovel treatment options for epilepsy: Focus on perampanel
Franco, V., Crema, F., Iudice, A., Zaccara, G., & Grillo, E. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.12.006 · Cited by 90
Self-citationCorrelation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma
Jaeckle, K. A., Ballman, K. V., Furth, A. F., & Buckner, J. C. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bbfeca · Cited by 89
Turck, B. J. D., Diltoer, M., Cornelis, P. J., et al. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.4.563 · Cited by 88
Pharmacokinetics of Aripiprazole and Concomitant Lithium and Valproate
Citrome, L., Josiassen, R. C., Bark, N. M., Salazar, D. E., & Mallikaarjun, S. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004269870 · Cited by 85
Perucca, E., & Kwan, P. (2005) · CNS Drugs · doi:10.2165/00023210-200519110-00001 · Cited by 84
Self-citationEbert, U., Thong, N. Q., Oertel, R., et al. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000146 · Cited by 83
Clinical Observations of Possible Barbiturate Interference With Anticoagulation
MacDonald, M. G. (1968) · JAMA · doi:10.1001/jama.1968.03140150001001 · Cited by 79
Gidal, B. E., Sheth, R. D., Parnell, J., Maloney, K., & Sale, M. E. (2003) · Epilepsy Research · doi:10.1016/j.eplepsyres.2003.09.008 · Cited by 79
Wong, Y. W. J., Yeh, C., & Thyrum, P. T. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200102000-00016 · Cited by 79
Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia
Kidron, R., Averbuch, I., Klein, E., & Belmaker, R. H. (1985) · Biological Psychiatry · doi:10.1016/0006-3223(85)90087-3 · Cited by 79
No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin
Andersen, B. B., Mikkelsen, M., Vesterager, A., Dam, M., Kristensen, H. B., Pedersen, B., Lund, J., & Mengel, H. B. (1991) · Epilepsy Research · doi:10.1016/0920-1211(91)90013-6 · Cited by 78
Novel Medications for Epilepsy
Fattore, C., & Perucca, E. (2011) · Drugs · doi:10.2165/11594640-000000000-00000 · Cited by 76
Self-citationDrug Treatment of Epilepsy in Elderly People: Focus on Valproic Acid
Stephen, L. J. (2003) · Drugs & Aging · doi:10.2165/00002512-200320020-00005 · Cited by 75
Interaction between Doxycycline and some Antiepileptic Drugs
Penttilä, O., Neuvonen, P. J., Aho, K., & LEHTOVAARA, R. (1974) · BMJ · doi:10.1136/bmj.2.5917.470 · Cited by 72
Adverse motor effects induced by antiepileptic drugs
Zaccara, G., Cincotta, M., Borgheresi, A., & Balestrieri, F. (2004) · Epileptic Disorders · doi:10.1684/j.1950-6945.2004.tb00064.x · Cited by 72
Self-citationCarbamazepine intoxication caused by interaction with isoniazid.
Valsalan, V. C., & Cooper, G. L. (1982) · BMJ · doi:10.1136/bmj.285.6337.261 · Cited by 70
Discontinuation of Phenytoin and Carbamazepine in Patients Receiving Felbamate
Wagner, M., Graves, N. M., Marienau, K., Holmes, G. B., Remmel, R. P., & Leppik, I. E. (1991) · Epilepsia · doi:10.1111/j.1528-1157.1991.tb04669.x · Cited by 70
Ono, S., Mihara, K., Suzuki, A., Kondo, T., Yasui‐Furukori, N., Furukori, H., de Vries, R., & Kaneko, S. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1056-8 · Cited by 66
Drug Interactions Between Lamotrigine and Psychoactive Drugs
Reimers, A., Skogvoll, E., Sund, J. K., & Spigset, O. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000169418.31275.a7 · Cited by 66
Oxcarbazepine Does Not Affect the Anticoagulant Activity of Warfarin
Krämer, G., Tettenborn, B., Jensen, P. K., Menge, G. P., & Stoll, K.-D. (1992) · Epilepsia · doi:10.1111/j.1528-1157.1992.tb01772.x · Cited by 66
Potential impact of valproic acid therapy on clozapine disposition
Finley, P. R., & Warner, D. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)90647-5 · Cited by 64
Galimberti, C. A., Mazzucchelli, I., Arbasino, C., Canevini, M. P., Fattore, C., & Perucca, E. (2006) · Epilepsia · doi:10.1111/j.1528-1167.2006.00629.x · Cited by 64
Self-citationCarbamazepine-induced Changes in Plasma Levels of Neuroleptics
Tiihonen, J., Vartiainen, H., & Hakola, P. (1995) · Pharmacopsychiatry · doi:10.1055/s-2007-979584 · Cited by 61
The Effect of Carbapenem Antibiotics on Plasma Concentrations of Valproic Acid
Mancl, E. E., & Gidal, B. E. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m296 · Cited by 61
Serum Concentrations of Valproic Acid
May, T., & Rambeck, B. (1985) · Therapeutic Drug Monitoring · doi:10.1097/00007691-198512000-00004 · Cited by 60
Effects of felbamate on the pharmacokinetics of phenobarbital
Reidenberg, P., Glue, P., Banfield, C. R., et al. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90244-9 · Cited by 60
Birbeck, G. L., French, J. A., Perucca, E., et al. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2011.03335.x · Cited by 59
Self-citationPharmacokinetic interaction between retigabine and lamotrigine in healthy subjects
Hermann, R., Knebel, N. G., Niebch, G., Richards, L. S., Borlak, J., & Locher, M. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0558-6 · Cited by 58
Clonazepam pharmacokinetics, brain uptake, and receptor interactions.
Greenblatt, D. J., Miller, L. G., & Shader, R. I. (1987) · PubMed · Cited by 56
Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects
Spaans, E., van den Heuvel, M. M., Schnabel, P. G., et al. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-002-0498-6 · Cited by 55
Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model
Botts, S. R., Díaz, F. J., Santoro, V., Spina, E., Muscatello, M. R. A., Cogollo, M. R., Castro, F. E., & de León, J. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.04.018 · Cited by 55
Spina, E., D’Arrigo, C., Santoro, V., Muscatello, M. R. A., Pandolfo, G., Zoccali, R. A., Díaz, F. J., & de León, J. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181c0590e · Cited by 54
Pharmacokinetics of Aripiprazole and Concomitant Carbamazepine
Citrome, L., Macher, J.-P., Salazar, D. E., Mallikaarjun, S., & Boulton, D. W. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318056f309 · Cited by 54
The effect of felbamate on valproic acid disposition
Wagner, M., Graves, N. M., Leppik, I. E., et al. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.170 · Cited by 54
Reduced Valproic Acid Serum Concentrations Due to Drug Interactions With Carbapenem Antibiotics
Park, M. K., Lim, K. S., Kim, T., et al. (2012) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318260f7b3 · Cited by 53
Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients
Wong, J. O.-Y., Leung, S.-P., Mak, T. W. L., et al. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.10.008 · Cited by 52
Ragueneau, I., Levy, R. H., & Meyerhoff, C. (2001) · Epilepsy Research · doi:10.1016/s0920-1211(01)00293-5 · Cited by 52
Stiripentol. A novel antiepileptic drug.
Trojnar, M. K., Wojtal, K., Trojnar, M. P., & Czuczwar, S. J. (2005) · PubMed · Cited by 52
(2008) · PubMed · Cited by 47
KAHN, E. M., Schulz, S. C., Perel, J. M., & ALEXANDER, J. E. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199002000-00011 · Cited by 47
Raitasuo, V., LEHTOVAARA, R., & HUTTUNEN, M. O. (1994) · Psychopharmacology · doi:10.1007/bf02244881 · Cited by 46
Spina, E., D’Arrigo, C., Migliardi, G., Santoro, V., Muscatello, M. R. A., Micò, U., D’Amico, G., & Perucca, E. (2006) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000246763.59506.b0 · Cited by 45
Self-citationMeltzer, H. Y., Bonaccorso, S., Bobo, W. V., Chen, Y., & Jayathilake, K. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m05997 · Cited by 45
REDUCED FELODIPINE BIOAVAILABILITY IN PATIENTS TAKING ANTICONVULSANTS
Capewell, S., Critchley, J., Freestone, S. H., et al. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90124-9 · Cited by 45
Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics*
Wong, S. L., Cavanaugh, J. H., Shi, H. H., Awni, W. M., & Granneman, G. R. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90166-6 · Cited by 41
Italian Consensus Conference on Epilepsy and Pregnancy, Labor and Puerperium
Aguglia, U., Barboni, G., Battino, D., Cavazzuti, G. B., Citernesi, A., Corosu, R., Guzzetta, F. M., Iannetti, P., Mamoli, D., Patella, A., et al. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2008.01964.x · Cited by 40
Self-citationRivers, F., O'Brien, T. J., & Callaghan, R. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.09.014 · Cited by 39
Nelson, M. H., Birnbaum, A. K., & Remmel, R. P. (2001) · Epilepsy Research · doi:10.1016/s0920-1211(00)00203-5 · Cited by 39
Inducing Effect of Phenobarbital on Clozapine Metabolism in Patients With Chronic Schizophrenia
Facciolà, G., Avenoso, A., Spina, E., & Perucca, E. (1998) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199812000-00008 · Cited by 38
Self-citationhomme, R. L. F. A. L., Dijkema, T., van der Ven, A. J. A. M., & Burger, D. M. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000234089.41785.c8 · Cited by 36
Plasma Concentrations of Risperidone and Olanzapine during Coadministration with Oxcarbazepine
Muscatello, M. R. A., Pacetti, M., Cacciola, M., Torre, D. L., Zoccali, R. A., Arrigo, C. D., Migliardi, G., & Spina, E. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.71104.x · Cited by 36
Winter, H. R., DeVane, C. L., Figueroa, C., Ennis, D. J., Hamer-Maansson, J. E., Davis, P. C., & Smith, M. A. (2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.869 · Cited by 35
Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects
Sidhu, J. S., Job, S., Bullman, J., Francis, E., Abbott, R. W., Ascher, J. A., & Theis, J. G. W. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02598.x · Cited by 35
The Pharmacology of New Antiepileptic Drugs: Does a Novel Mechanism of Action Really Matter?
Perucca, E. (2011) · CNS Drugs · doi:10.2165/11587900-000000000-00000 · Cited by 34
Self-citationStatus Epilepticus Associated with the Combination of Valproic Acid and Clomipramine
DeToledo, J. C., Haddad, H., & Ramsay, R. E. (1997) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199702000-00012 · Cited by 33
The adverse event profile of pregabalin across different disorders: a meta-analysis
Zaccara, G., Perucca, P., & Gangemi, P. F. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1213-x · Cited by 32
Self-citationEffect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children
Tran, A., Vauzelle-Kervroedan, F., Rey, E., Pons, G., d'Athis, P., Chiron, C., Dulac, O., Renard, F., & Olivé, G. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050147 · Cited by 30
Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects
Sitsen, J. M. A., Maris, F. A., & Timmer, C. J. (2001) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190384 · Cited by 28
Migliardi, G., D’Arrigo, C., Santoro, V., Bruno, A., Cortese, L., Campolo, D., Cacciola, M., & Spina, E. (2007) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000240955.49315.65 · Cited by 27
INTERACTIONS OF ANTICONVULSANT DRUGS WITH MIANSERIN AND NOMIFENSINE
Nawishy, S., Hathway, N. R., & Turner, P. (1981) · The Lancet · doi:10.1016/s0140-6736(81)91134-x · Cited by 27
AMPA receptor inhibitors for the treatment of epilepsy: the role of perampanel
Zaccara, G., Giovannelli, F., Cincotta, M., & Iudice, A. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/ern.13.46 · Cited by 26
Self-citationReduced Plasma Nisoldipine Concentrations in Phenytoin‐Treated Patients with Epilepsy
Michelucci, R., Cipolla, G., Passarelli, D., et al. (1996) · Epilepsia · doi:10.1111/j.1528-1157.1996.tb01032.x · Cited by 26
Yamamoto, Y., Takahashi, Y., Imai, K., Mogami, Y., Matsuda, K., Nakai, M., Kagawa, Y., & Inoue, Y. (2014) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2014.03.018 · Cited by 25
Significant reduction of sertraline plasma levels by carbamazepine and phenytoin
Pihlsgård, M., & Eliasson, E. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-001-0416-3 · Cited by 24
Factors contributing to carbamazepine–macrolide interactions
Pauwels, O. S. G. (2002) · Pharmacological Research · doi:10.1006/phrs.2002.0957 · Cited by 24
Serum Valproate Levels with Oral Contraceptive Use
Herzog, A. G., Farina, E. L., & Blum, A. S. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.00605.x · Cited by 23
Contraception for women taking antiepileptic drugs
O’Brien, M. D., & Guillebaud, J. (2010) · Journal of Family Planning and Reproductive Health Care · doi:10.1783/147118910793048764 · Cited by 23
Sachdeo, R., Wagner, M., Sachdeo, S. K., et al. (1999) · Epilepsia · doi:10.1111/j.1528-1157.1999.tb00829.x · Cited by 18
Warfarin-Felbamate Interaction: First Report
Tisdel, K. A., Israel, D. S., & Kolb, K. W. (1994) · Annals of Pharmacotherapy · doi:10.1177/106002809402800620 · Cited by 16
Hassan, Y., Awaisu, A., Aziz, N. A., et al. (2005) · Pharmacy World & Science · doi:10.1007/s11096-004-5150-3 · Cited by 14
Elevated Plasma Clozapine Concentrations After Phenobarbital Discontinuation
Lane, H., Su, K., Chang, W., & Jann, M. W. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0308b · Cited by 14
Santucci, R., Fothergill, H., Laugel, V., Pervillé, A., Martin, A. D. S., Gérout, A. C., & Fischbach, M. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03593.x · Cited by 14
The Interaction Potential of Retigabine (Ezogabine) with Other Antiepileptic Drugs
Tompson, D. J., & Crean, C. S. (2014) · Current Clinical Pharmacology · doi:10.2174/1574884708666131111192311 · Cited by 10
Bertschy, G., Vandel, S., Jounet, J. M., et al. (1990) · PubMed · Cited by 8
Glauser, T. A. (2004) · Wiley eBooks · doi:10.1002/9780470752463.ch32 · Cited by 1
Cited by
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
30 years of second-generation antiseizure medications: impact and future perspectives
Perucca, E., Brodie, M. J., Kwan, P., & Tomson, T. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30035-1 · Cited by 261
Self-citationPharmacodynamic interactions of antiepileptic drugs: From bench to clinical practice
Verrotti, A., Lattanzi, S., Brigo, F., & Zaccara, G. (2020) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2020.106939 · Cited by 82
Self-citationMorbidity in depressive disorders
Baldessarini, R. J., Forte, A., Selle, V., Sim, K., Tondo, L., Undurraga, J., & Vázquez, G. H. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000448661 · Cited by 63
Arroyo, G., Bustos, J. A., Lescano, A. G., Gonzales, I., Saavedra, H., Rodriguez, S., Pretell, E. J., Bonato, P. S., Lanchote, V. L., Takayanagui, O. M., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz085 · Cited by 19
Metadata
- Authors
- Zaccara, G., & Perucca, E.
- Venue
- Epileptic Disorders
- Publisher
- Wiley
- Published
- 2014-12
- Volume
- 16
- Issue
- 4
- Pages
- 409-431
- ISSN
- 1294-9361 (ISSN-L)
- 1950-6945
- OpenAlex
- W1960629422
- Cited by
- 305
- References
- 141
- FWCI
- 11.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.